. 2020 Sep 26;8(18):4010–4016. doi: 10.12998/wjcc.v8.i18.4010

Table 2.

Comparison of levels of bone mineral density and bone metabolic markers between the two groups

Groups	n	BMD, g/cm²		N-MID, ng/mL	β-CTx, pg/mL	25(OH)D, ng/mL
Groups	n	Lumbar L_1-4	Hip	N-MID, ng/mL	β-CTx, pg/mL	25(OH)D, ng/mL
Control group
Before the treatment	60	0.71 ± 0.13	0.62 ± 0.09	19.35 ± 8.14	498.57 ± 210.02	9.54 ± 3.67
After the treatment	60	0.88 ± 0.17^a	0.76 ± 0.15^a	15.54 ± 5.23	376.27 ± 157.45	17.97 ± 5.74
Experimental group
Before the treatment	60	0.73 ± 0.11	0.64 ± 0.08	20.41 ± 8.13	504.74 ± 237.41	9.23 ± 2.84
After the treatment	60	1.04 ± 0.25^a ^b	0.93 ± 0.20^a ^b	10.68 ± 4.24^a ^b	310.64 ± 146.83^a ^b	25.96 ± 6.91^a ^b

P < 0.05 vs before the treatment;

P < 0.05 vs the control group after the treatment. 25(OH)D: 25-hydroxyvitamin D; β-CTx: β-isomerized C-terminal telopeptides; BMD: Bone mineral density; N-MID: N-terminal midfragment.